IndiSwitch Product Lifecycle Management with valuable IP
In the prevailing patent regime, the discovery of New Indications for approved drugs acts as an important Product Lifecycle Management strategy.
If you have a product in the market which is getting off-patent or a product that is not meeting its business objectives in the approved area, we can help you in discovering new indications where it can have a protectable intellectual property position.
We undertake New Indication research deploying three independent approaches which ensure extensive exploration and hardly leave chance of false negatives and false positives. This research is carried out by expert VLife scientists who have a sterling track record in discovery of new indications and is enabled by our computational technologies and a multi core parallel processing computational cluster.
We cover the following work-flow with the scope of engagement with client covering some or all of the following steps:
Our expertise in computational discovery Success with computation technology requires awareness of not only its strengths but also of the areas where it needs augmentation from other approaches. Being developers of computational technologies, we have proved our expertise by creating IP in 3 NCE classes and 7 new indication discoveries.
Wide diversity of experience We cater to a variety of sectors and within them, a diversity of areas. e.g. in pharmaceuticals, we have successfully delivered discovery projects in oncology, anti-fungal, diabetes, CNS etc.
State-of-art technology portfolio Clients benefit from the whole range of VLife's technologies having validated algorithms, published innovations and efficient workflows which are accessible to clients through VLife services.
In-house custom development skills Generic technologies sometimes are inadequate or inefficient in complex research. For such needs, our in-house team has skills to develop custom technologies ensuring reliable research.